APACR vs SRPT
StoneBridge Acquisition II Corporation Rights (APACR) versus Sarepta Therapeutics Inc (SRPT) — a side-by-side from cached financials, not a winner call.
StoneBridge Acquisition II Corporation Rights (APACR) common stock listed on NASDAQ.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
APACR does not have a complete income-statement cache yet.
Latest reported SRPT revenue for 2026-06-30 was $1.13B. Net income was $326.1M. Revenue was up 54.9% from 2026-03-31 to 2026-06-30. SRPT currently screens at market cap $2.34B.
APACR currently screens at market cap $0. SRPT currently screens at market cap $2.34B.
Not investment advice. Open the APACR and SRPT stock pages for the full models.
Not investment advice.